Optinose Us Inc Drug Patent Portfolio

Optinose Us Inc owns 1 orange book drug protected by 19 US patents Given below is the list of Optinose Us Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11554229 Nasal administration 23 Feb, 2036
Active
US10300229 Nasal delivery devices 07 Jul, 2035
Active
US10076614 Nasal delivery devices 20 Oct, 2034
Active
US10478574 Nasal administration 04 Nov, 2033
Active
US10179216 Nasal delivery devices 08 Jul, 2033
Active
US11033696 Nasal delivery devices 20 May, 2033
Active
US10252010 Nasal delivery devices 07 Feb, 2031
Active
US8978647 Nasal delivery 06 Dec, 2030
Active
US8550073 Nasal delivery 22 Oct, 2029
Active
US10076615 Nasal delivery 30 Jul, 2029
Active
US11602603 Nasal delivery devices 27 Oct, 2028
Active
US10124132 Nasal delivery 06 Mar, 2027
Active
US7975690 Nasal devices 29 Dec, 2025
Active
US8522778 Nasal devices 20 Apr, 2024 Expired
US8327844 Nasal delivery method 24 Oct, 2023 Expired
US9072857 Nasal delivery device 10 Apr, 2021 Expired
US6715485 Nasal delivery device 03 Sep, 2020 Expired
US9468727 Nasal delivery 30 Jul, 2020 Expired
US8555878 Nasal delivery device 20 Mar, 2020 Expired


Given below is the list of recent legal activities going on the following drug patents of Optinose Us Inc.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 10 Jun, 2024 US9468727
Expire Patent 14 Aug, 2023 US9072857
Patent Issue Date Used in PTA Calculation 14 Mar, 2023 US11602603
Recordation of Patent Grant Mailed 14 Mar, 2023 US11602603
Maintenance Fee Reminder Mailed 27 Feb, 2023 US9072857
Email Notification 23 Feb, 2023 US11602603
Issue Notification Mailed 22 Feb, 2023 US11602603
Application Is Considered Ready for Issue 15 Feb, 2023 US11602603
Dispatch to FDC 15 Feb, 2023 US11602603
Issue Fee Payment Verified 14 Feb, 2023 US11602603
Issue Fee Payment Received 14 Feb, 2023 US11602603
Patent Issue Date Used in PTA Calculation 17 Jan, 2023 US11554229
Recordation of Patent Grant Mailed 17 Jan, 2023 US11554229
Email Notification 29 Dec, 2022 US11554229
Issue Notification Mailed 28 Dec, 2022 US11554229


Optinose Us Inc Drug Patents' Oppositions Filed in EPO

Optinose Us Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 27, 2005, by Direct-Haler A/S. This opposition was filed on patent number EP00906570A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17190469A Aug, 2021 Beck Greener LLP Granted and Under Opposition
EP08736896A Jun, 2021 Beck Greener LLP Patent maintained as amended
EP13715145A Sep, 2020 ELKINGTON AND FIFE LLP Granted and Under Opposition
EP00906570A Sep, 2005 Direct-Haler A/S Opposition rejected


Optinose Us Inc's Family Patents

Optinose Us Inc drugs have patent protection in a total of 30 countries. It's US patent count contributes only to 19.2% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Optinose Us Inc Drug List

Given below is the complete list of Optinose Us Inc's drugs and the patents protecting them.


1. Xhance

Xhance is protected by 19 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11554229 Nasal administration 23 Feb, 2036
(11 years from now)
Active
US10300229 Nasal delivery devices 07 Jul, 2035
(10 years from now)
Active
US10076614 Nasal delivery devices 20 Oct, 2034
(10 years from now)
Active
US10478574 Nasal administration 04 Nov, 2033
(9 years from now)
Active
US10179216 Nasal delivery devices 08 Jul, 2033
(8 years from now)
Active
US11033696 Nasal delivery devices 20 May, 2033
(8 years from now)
Active
US10252010 Nasal delivery devices 07 Feb, 2031
(6 years from now)
Active
US8978647 Nasal delivery 06 Dec, 2030
(6 years from now)
Active
US8550073 Nasal delivery 22 Oct, 2029
(5 years from now)
Active
US10076615 Nasal delivery 30 Jul, 2029
(4 years from now)
Active
US11602603 Nasal delivery devices 27 Oct, 2028
(4 years from now)
Active
US10124132 Nasal delivery 06 Mar, 2027
(2 years from now)
Active
US7975690 Nasal devices 29 Dec, 2025
(1 year, 2 months from now)
Active
US8522778 Nasal devices 20 Apr, 2024
(5 months ago)
Expired
US8327844 Nasal delivery method 24 Oct, 2023
(11 months ago)
Expired
US9072857 Nasal delivery device 10 Apr, 2021
(3 years ago)
Expired
US6715485 Nasal delivery device 03 Sep, 2020
(4 years ago)
Expired
US9468727 Nasal delivery 30 Jul, 2020
(4 years ago)
Expired
US8555878 Nasal delivery device 20 Mar, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xhance's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List